ROSG Key Stats
- Rosetta Genomics Issues Letter to Shareholders noodls Dec 2
- Rosetta Genomics to Participate in the LD Micro Conference noodls Nov 27
- Rosetta Genomics Expands microRNA Cancer Testing Services Agreement With GeneKor to Include Turkey and Romania noodls Nov 20
- Rosetta Genomics Granted U.S. Patent Allowance for the Use of microRNAs to Treat Liver Cancer Marketwired Nov 7
- Rosetta Genomics Reports First Payment From the UK's National Health Service for the Rosetta Cancer Origin Test(TM) Marketwired Nov 6
- Rosetta Genomics announces sponsored research agreement with Ramot at TAU Oct 31
- Rosetta Genomics Announces Sponsored Research Agreement With Ramot at Tel Aviv University noodls Oct 31
- Aegis Capital Cuts Rosetta Genomics (ROSG) to Hold; Diagnostics Tests Continue to Lag Street Insider Oct 30
- Rosetta Genomics downgraded by Aegis Capital Oct 30
- Rosetta Genomics receives USPTO patent for lung cancer test Oct 22
ROSG Total Returns Comparison
This total returns chart shows the returns to an investor from both price appreciation and dividends (dividends are assumed to be reinvested). Rosetta Genomics is down 29.77% over the last year vs S&P 500 Total Return up 26.99%, Genetic Technologies down 41.27%, and Agilent Technologies up 37.56%.
Fundamental analysis of a business involves analyzing its financial statements and health, its management and competitive advantages. The key financial statements of a company are the income statement, balance sheet and cash flow statement.
Income Statement View Statement
Balance Sheet View Statement
Pro Ratings for ROSG
Pro Strategies Featuring ROSG
Did Rosetta Genomics make it into our Pro Portfolio Strategies?
Start your YCharts Pro membership now to find out.
Rosetta Genomics, Ltd., develops diagnostic tests and therapeutic tools. Its product portfolio comprises of tests such as miRview mets2/mets, miRview squamous, miRview meso and miRview kidney.